MetLife Investment Management LLC lifted its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating) by 2.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 48,717 shares of the biopharmaceutical company’s stock after purchasing an additional 1,135 shares during the period. MetLife Investment Management LLC owned about 0.05% of Intra-Cellular Therapies worth $2,267,000 at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in ITCI. US Bancorp DE increased its position in Intra-Cellular Therapies by 93.8% in the 2nd quarter. US Bancorp DE now owns 496 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 240 shares during the period. Assetmark Inc. increased its position in Intra-Cellular Therapies by 410.0% in the 2nd quarter. Assetmark Inc. now owns 510 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 410 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Intra-Cellular Therapies in the 3rd quarter valued at about $41,000. Northern Oak Wealth Management Inc. acquired a new position in Intra-Cellular Therapies in the 2nd quarter valued at about $51,000. Finally, Quantbot Technologies LP purchased a new stake in Intra-Cellular Therapies in the 3rd quarter valued at approximately $55,000. Institutional investors and hedge funds own 86.95% of the company’s stock.
Intra-Cellular Therapies Stock Performance
ITCI opened at $47.32 on Monday. The business’s fifty day moving average is $49.37 and its two-hundred day moving average is $49.69. The company has a market cap of $4.48 billion, a price-to-earnings ratio of -14.25 and a beta of 1.10. Intra-Cellular Therapies, Inc. has a one year low of $42.42 and a one year high of $66.00.
Insiders Place Their Bets
Analysts Set New Price Targets
ITCI has been the subject of several recent analyst reports. Canaccord Genuity Group raised their price target on Intra-Cellular Therapies from $90.00 to $93.00 in a report on Friday, November 4th. Needham & Company LLC reaffirmed a “buy” rating and set a $70.00 price objective on shares of Intra-Cellular Therapies in a report on Friday, February 10th. StockNews.com raised Intra-Cellular Therapies from a “sell” rating to a “hold” rating in a report on Friday, November 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $83.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, February 1st. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, Intra-Cellular Therapies has a consensus rating of “Moderate Buy” and a consensus target price of $71.38.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc operates as a biopharmaceutical company. It focuses on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS.
- Get a free copy of the StockNews.com research report on Intra-Cellular Therapies (ITCI)
- MarketBeat Week in Review – 2/20 – 2/24
- Carvana Skidding On Revenue Decrease, Heavy Debt Burden
- What Are Consumer Staples Stocks?
- Is Rocky Brands Dividend A Good Fit For Your Portfolio?
- Beyond Meat Stock Is Not Beyond Hope
Want to see what other hedge funds are holding ITCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Rating).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.